Bullish case
$702 to $1,030
More likely if Tyvaso DPI growth offsets nebulized Tyvaso pressure, new clinical results broaden the addressable market, pipeline programs progress, and the market accepts a 20x to 25x earnings multiple.
United Therapeutics Corporation research snapshot
UTHR AI Stock Analysis
UTHR AI stock analysis sees United Therapeutics as a profitable rare-disease company whose Tyvaso franchise, cash-rich balance sheet, share repurchase program, and cardiopulmonary pipeline support the business-quality case. The counterweight is that Q1 2026 revenue fell 2%, Tyvaso mix is shifting, and clinical, competitive, and valuation outcomes can move the shares quickly. At the July 9, 2026 data cutoff, UTHR closed at $552.48 and price multiplied by 42.45 million shares produced a market capitalization near $23.45 billion. This UTHR AI stock analysis is an informational research tool, not investment advice.
Current price
$552.48
Market cap
$23.45 billion
AI score
76 / 100
Rating
Profitable rare-disease franchise with pipeline and competition risk
Trend status
Range-bound near moving averages after a strong year
Data cutoff (updated weekly)
July 9, 2026
Informational use only. This page is not investment advice.
Research quality check
- information Richness
- A-level information richness. United Therapeutics has long public filings, quarterly releases, product-level revenue disclosure, clinical updates, and active third-party financial coverage.
- bias Check
- The main AI bias risk is extrapolating a high-margin Tyvaso franchise as if it has no competitive or patent risk. The review gives equal weight to Tyvaso mix, pipeline readouts, reimbursement, clinical execution, and the gap between business quality and entry price.
- ai Confidence
- High data confidence
- investment Certainty
- Medium. Reported financial data and current product economics are well documented, while clinical readouts, competition, label expansion, and future pricing are inherently uncertain.
Quick verdict table
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | United Therapeutics sells therapies for pulmonary arterial hypertension and related serious diseases, with Tyvaso as the largest commercial franchise. | High |
| Moat | Specialist prescriber relationships, drug delivery know-how, commercial infrastructure, regulatory approvals, and cash-funded R&D support the moat, but patents and clinical differentiation require continued defense. | Medium-high |
| Management | Chairperson and CEO Martine Rothblatt has built a rare-disease business and funds pipeline and organ-manufacturing work. The key capital-allocation test is balancing R&D, buybacks, and disciplined clinical investment. | Medium-high |
| Financial trend | FY2025 revenue was $3.18 billion and net income was $1.34 billion. Q1 2026 revenue was $781.5 million, down 2% year over year, while net income was $274.9 million. | High |
| Valuation | financial_rigor.py verified about 20.39x TTM EPS and 25.82x TTM free cash flow per share at the July 9 close. That valuation needs sustained earnings and credible pipeline progress. | Medium |
| Technical trend | The July 9 close sat slightly above the July 6 50-day and 200-day simple moving averages, while momentum indicators were mixed. | Medium |
| Risk level | Risk is medium-high because a concentrated product portfolio, competition, trial outcomes, reimbursement, and policy changes can outweigh a strong balance sheet. | Medium-high |
| AI confidence | High for financial history and product revenue. Medium for clinical probabilities, technical levels, and scenario valuation. | High data confidence |
| Investment certainty | Medium. The core franchise and net cash are tangible, but future returns depend on durability beyond current Tyvaso economics and the price paid. | Medium |
UTHR AI stock forecast
UTHR AI Stock Forecast Scenarios
The UTHR AI stock forecast uses scenario ranges around the $552.48 July 9 close, not a point target. A financial_rigor.py three-scenario calculation using $27.09 TTM EPS produced mechanical three-year outputs near $1,030 in a bull case, $702 in a base case, and $431 in a bear case. Those are valuation frameworks, not predictions.
Base case
$552 to $702
More likely if commercial revenue returns to growth, margins remain strong, buybacks reduce shares, and investors value the company near 20x earnings while waiting for pipeline evidence.
Bearish case
$431 to $552
More likely if Tyvaso demand weakens, competitors or generic risk pressure revenue, clinical programs disappoint, or the market assigns a lower multiple to a concentrated franchise.
UTHR AI technical analysis
UTHR AI Technical Analysis
UTHR AI technical analysis uses the $552.48 July 9, 2026 close and the latest independently available indicator snapshot from July 6. It showed a $547.32 50-day simple moving average, a $549.78 200-day simple moving average, RSI(14) of 46.575, and ATR(14) of 4.7601. Confirm live chart data before using any level.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $552.48 | StockAnalysis regular-session close on July 9, 2026. |
| Near support | $547 to $550 | The July 6 50-day and 200-day simple moving averages clustered in this zone. |
| Near resistance | $563 to $609 | $563.70 was the July 7 high in the quote snapshot and $609.35 was the cited 52-week high. |
| 50-day moving average | $547.32 | Investing.com July 6 simple moving average snapshot. The July 9 close was above it. |
| 200-day moving average | $549.78 | Investing.com July 6 simple moving average snapshot. The July 9 close was only slightly above it. |
| Momentum | Mixed | RSI(14) was 46.575 and MACD was 0.47 in the July 6 snapshot. Neither replaces a fresh chart review. |
| Volume | Monitor on breakouts | Use volume confirmation on a move through resistance because pharma news can create sharp one-day moves. |
| Volatility | ATR(14) about $4.76 | The July 6 technical snapshot described this as lower volatility, but earnings and clinical events can change that quickly. |
| Invalidation | Sustained close below $547 | A sustained break below the moving-average cluster would weaken a trend-following setup and requires a fresh fundamental review. |
UTHR AI trading strategy
UTHR AI Trading Strategy Framework
The UTHR AI trading strategy is a research framework for a clinical and regulatory-sensitive healthcare stock. It is not personal advice. Use position sizing, an earnings calendar, live chart confirmation, and explicit invalidation rules.
Trend-following setup
Watch whether UTHR holds above the $547 to $550 moving-average cluster and then clears the recent $563 area with confirming volume. Recheck the July 29 estimated earnings date and material clinical or regulatory events.
A sustained move below the moving-average cluster or a negative revenue, trial, or regulatory update invalidates the setup.
Mean-reversion setup
Only consider a rebound framework after price stabilizes near support and Tyvaso demand, reimbursement, and pipeline news remain consistent with the thesis.
Do not average down through a support break caused by worsening Tyvaso trends, a clinical setback, or new competitive evidence.
Fundamental monitor
Track Tyvaso DPI and nebulized Tyvaso sales, Orenitram, operating margin, cash and investments, repurchase execution, trial readouts, label expansion, and reimbursement changes.
Lower confidence if product concentration rises, revenue growth stalls, or R&D spending fails to produce credible commercial options.
Investment research summary
Four-master Research Compression
Business essence
Patients and specialist prescribers use United Therapeutics therapies to treat serious cardiopulmonary disease. The company earns most revenue from medicines and delivery systems, especially Tyvaso.
Moat
The moat combines approved therapies, specialist relationships, drug-delivery experience, regulatory knowledge, and a cash position that supports clinical development. It is not permanent because rare-disease markets attract competition and patents expire.
Munger risk inversion
The thesis fails if investors treat Tyvaso as a perpetual annuity while competitors, generic exposure, reimbursement pressure, or a weaker product mix reduce growth before the pipeline can replace it.
Management
Management has a long record of investing in rare disease and adjacent organ-manufacturing work. The current question is whether R&D and the $2.0 billion authorization create more value than simply preserving net cash.
Industry trend
Pulmonary hypertension diagnosis and treatment are specialized, science-driven markets. New delivery formats and label expansion can grow demand, while drug competition, payer control, and trial risk limit simple long-term extrapolation.
Valuation and margin of safety
At about 20x TTM earnings and 26x TTM free cash flow per share, the price recognizes a profitable business and net cash. Margin of safety improves if revenue durability is proven or if the entry multiple falls.
Source-backed data
UTHR Data Table
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| UTHR price | $552.48 at the July 9 close | StockAnalysis quote snapshot | July 9, 2026 |
| Market capitalization | $23.45 billion, price times 42.45M shares | StockAnalysis quote plus financial_rigor.py verification | July 9, 2026 |
| Shares outstanding | 42.45 million | United Therapeutics Q1 2026 Form 10-Q and StockAnalysis | July 9, 2026 |
| FY2025 revenue | $3.183 billion, up 10.61% | SEC 10-K, Macrotrends, and StockAnalysis | July 9, 2026 |
| FY2025 net income | $1.335 billion, up 11.68% | SEC 10-K, Macrotrends, and StockAnalysis | July 9, 2026 |
| Q1 2026 revenue | $781.5 million, down 2% year over year | United Therapeutics Q1 2026 results | July 9, 2026 |
| Q1 2026 net income | $274.9 million, down 15% year over year | United Therapeutics Q1 2026 results | July 9, 2026 |
| Q1 2026 Tyvaso revenue | $457.5 million, down 2% year over year | United Therapeutics Q1 2026 results | July 9, 2026 |
| Cash and short-term investments | $2.154 billion at March 31, 2026 | SEC 10-Q, Macrotrends, and StockAnalysis | July 9, 2026 |
| Share repurchase authorization | $2.0 billion authorized in March 2026 | United Therapeutics Q1 2026 results | July 9, 2026 |
| Technical snapshot | 50-day SMA $547.32, 200-day SMA $549.78, RSI(14) 46.575 | Investing.com technical page, July 6 snapshot | July 9, 2026 |
Frequently Asked Questions
Read the RPRX AI stock analysisView the REGN AI stock forecastExplore the VRTX AI technical analysisScreen AI stock picker ideasBuild an AI trading strategyCompare healthcare stocks
This UTHR AI stock analysis page is an informational tool only and is not investment advice, a recommendation, or a promise of future returns. Forecast scenarios use available public data as of July 9, 2026 and can be wrong if fundamentals, clinical results, valuation, technical trends, or market conditions change.
Related Tools
Trading Strategy Builder
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Try it
Stock Screener
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Try it
AI Stock Picker & Screener
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
Try it